Upstream Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference
Upstream Bio (Nasdaq: UPB) will present at the 44th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Upstream Bio (Nasdaq: UPB) will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 at 2:15 p.m. PT. Rand Sutherland, MD, Chief Executive Officer, will deliver the presentation. A live webcast will be available under the Events tab on the Investors section of Upstream Bio’s website on the day of the event, and a replay will be posted on the company website after the presentation.
Details
News Market Reaction – UPB
On Jan 5, the day this news came out, UPB closed 3.47% below the previous close.
Data tracked by StockTitan Argus for the Jan 5 session.
Key Figures
- Conference edition
- 44th Annual J.P. Morgan Healthcare Conference
- Event where CEO presentation is scheduled
- Presentation date
- January 12, 2026
- Scheduled conference presentation date
- Presentation time
- 2:15 p.m. PT
- Scheduled time of J.P. Morgan presentation
Historical Context
-
Announcement of CEO participation in two December 2025 investor conferences.
-
Q3 2025 results with positive Phase 2 CRSwNP data and solid cash runway.
-
Planned CEO participation in three November 2025 healthcare investor events.
-
Presentation of structural and mechanistic data supporting verekitug’s differentiated profile.
-
Announcement of CEO fireside chat at Stifel 2025 Virtual Immunology Forum.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will be presenting at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 2:15 p.m. PT.
A live webcast of the presentation will be available under the Events tab on the Investors section of Upstream Bio’s website on the day of the event. A replay will be available on the Company's website following the presentation.
About Upstream Bio
Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. Upstream Bio is developing verekitug, the only known antagonist currently in clinical development that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. Upstream Bio has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma and chronic obstructive pulmonary disease (COPD). Upstream Bio’s team is committed to maximizing verekitug’s unique attributes to address the substantial unmet needs for patients underserved by today’s standard of care. To learn more, please visit www.upstreambio.com.
Investor and Media Contact:
Meggan Buckwell
Director, Corporate Communications and Investor Relations
ir@upstreambio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.